Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 28, 2026

Crypto News Today: Pepeto Project News While Bull Run Signals Align and Dogecoin SEC Commodity Ruling Opens the Door for What Comes Next

View original at globenewswire.com
Crypto News Today: Pepeto Project News While Bull Run Signals Align and Dogecoin SEC Commodity Ruling Opens the Door for What Comes Next Dubai, UAE, March 28, 2026 (GLOBE NEWSWIRE) -- Pepeto pushed past $8.47 million after its latest round closed ahead of schedule while the crypto news today delivered the catalysts thi…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Binance listing is happening in the few days comings

    60% confidence

  • Analyst targets for Dogecoin in this bull run sit between $0.20 and $0.47, a respectable 2x to 5x for holders

    60% confidence

  • Dogecoin reached $85 billion market cap on community alone and then lost 93% because there was nothing generating demand once the attention moved on

    60% confidence

  • Pepeto presale rounds close faster every week

    60% confidence

  • Pepeto organic growth is already outpacing what the team expected

    60% confidence

  • Active wallet addresses jumped 176% in one week

    60% confidence

  • Binance long ratio on Dogecoin flipped bullish for the first time in months

    60% confidence

Data points we hold from this source

Pepeto · funds raised8.47 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Crypto News Today: Pepeto Project News While Bull Run Signals Align and Dogecoin SEC Commodity Ruling Opens the Door for What Comes Next — Source | Via News | ViaNews EU